Get the Stockscreener App
1.30
2.26%
-0.03
After Hours:
1.31
0.01
+0.77%
Palisade Bio Inc stock is traded at $1.30, with a volume of 57,498.
It is down -2.26% in the last 24 hours and down -40.91% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.33
Open:
$1.33
24h Volume:
57,498
Relative Volume:
0.04
Market Cap:
$3.86M
Revenue:
-
Net Income/Loss:
$-14.07M
P/E Ratio:
-0.0929
EPS:
-13.99
Net Cash Flow:
$-12.56M
1W Performance:
-9.09%
1M Performance:
-40.91%
6M Performance:
-63.99%
1Y Performance:
-80.91%
1-Day Range:
$1.29
$1.35
1-Week Range:
$1.25
$1.43
52-Week Range:
$1.25
$9.65
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.30 | 3.86M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Palisade Bio Inc Stock (PALI) Latest News
Reviewing Protara Therapeutics (NASDAQ:TARA) and Palisade Bio (NASDAQ:PALI) - Defense World
JPMorgan Chase & Co. Purchases Shares of 8,200 Palisade Bio, Inc. (NASDAQ:PALI) - Defense World
PALI stock touches 52-week low at $1.32 amid market challenges - Investing.com
Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress - The Manila Times
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress - GlobeNewswire
PALI stock plunges to 52-week low, touches $1.34 - Investing.com India
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - The Manila Times
Palisade Bio CEO to Present at Webull Healthcare Investment Webinar This January - StockTitan
Palisade Bio reports positive data for UC drug trial - MSN
Palisade Bio begins MAD cohorts of Phase Ia/b ulcerative colitis therapy trial - Yahoo! Voices
Puma Samples 601.33 g/t Gold at its McKenzie Gold Project - The Manila Times
Palisade Bio Completes All Five SAD Cohorts and Advances to - GlobeNewswire
Palisade Bio's Ulcerative Colitis Drug PALI-2108 Shows Strong Safety Profile in Phase 1 Study - StockTitan
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Palisade Bio Awards Stock Options to New Employee Under Inducement Plan - StockTitan
Palisade Bio (NASDAQ:PALI) Trading Up 2.9% – Here’s What Happened - Defense World
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board - Markets Insider
Dr. Brian Feagan Appointed to Palisade Bio Clinical Advisory Board - citybiz
Palisade Bio Strengthens Clinical Advisory Board with Leading Gastroenterology Expert for UC Drug Development - StockTitan
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan
AleAnna, Inc. Announces Completion of Business Combination between Swiftmerge Acquisition Corp. and AleAnna Energy, LLC - The Manila Times
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - GlobeNewswire
Palisade Bio Raises $5M in Public Offering to Advance Phase 1 Clinical Trial Pipeline - StockTitan
What's Going On With Palisade Bio Stock On Thursday? - Benzinga
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - The Manila Times
Palisade Bio Raises $5M in Public Offering to Advance Key Clinical Trial of PALI-2108 - StockTitan
Nasdaq Down 50 Points; US Initial Jobless Claims Rise - Benzinga
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
PALI Stock Plummets to 52-Week Low at $2.13 Amid Market Struggles - Investing.com
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects - GlobeNewswire
Palisade Bio Reports Promising Safety Data in Phase 1 Ulcerative Colitis Drug Trial | PALI Stock News - StockTitan
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
Brookline Capital Management Estimates Palisade Bio FY2024 Earnings - Defense World
Palisade Bio to Present Preclinical Results for PALI-2108 - GlobeNewswire
Palisade Bio's PALI-2108 Shows Promise in Preclinical IBD Treatment Study | PALI Stock News - StockTitan
Brookline Capital Initiates Coverage of Palisade Bio (PALI) with Buy Recommendation - MSN
AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults - Pharmaceutical Technology
ARMISTICE CAPITAL, LLC Acquires Shares in Palisade Bio Inc - GuruFocus.com
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit - The Manila Times
Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Palisade Bio Inc (PALI) Quarterly 10-Q Report - Quartzy
Palisade Bio Reports Third Quarter 2024 Financial Results - GlobeNewswire
Palisade Bio Advances UC Drug Trial: Key Phase 1 Milestones & Patent Wins Boost Pipeline | PALI Stock News - StockTitan
Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 - Yahoo Finance
Palisade Bio initiates phase 1 study of new UC drug - Investing.com
Palisade Bio initiates phase 1 study of new UC drug By Investing.com - Investing.com Australia
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) - The Manila Times
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights - The Manila Times
Palisade Bio Announces First Subject Dosed in Phase 1 - GlobeNewswire
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):